Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.35 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174859 | 0.90 | RORC (0.39) | RORCTYK2PPARGCYP3A4CYP2C9 | |
| SCHEMBL7182323 | 0.88 | RORC (0.36) | RORCTYK2PPARGCYP2C9ALDH1A1 | |
| SCHEMBL7182217 | 0.86 | MAPT (0.39) | RORCTYK2CYP2C9ALDH1A1MAPT | |
| SCHEMBL7182450 | 0.86 | FABP3 (0.39) | RORCTYK2CYP2C9ALDH1A1MAPT | |
| SCHEMBL7189010 | 0.85 | SLC6A9 (0.41) | RORCTYK2MAPTGAA | |
| SCHEMBL7182455 | 0.85 | ALDH1A1 (0.38) | ALDH1A1ALOX12MAPTNPSR1KCNK3 | |
| SCHEMBL7190138 | 0.81 | KMT2A (0.40) | ALDH1A1MAPTKCNK3KCNK9GAA | |
| SCHEMBL7180547 | 0.81 | ALDH1A1 (0.38) | ALDH1A1MAPTNPSR1KCNK3KCNK9 | |
| SCHEMBL7181260 | 0.81 | ALDH1A1 (0.38) | CYP2C9ALDH1A1ALOX12MAPTNPSR1 | |
| SCHEMBL7180976 | 0.81 | TYK2 (0.43) | RORCTYK2PPARGCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | RORC 1336/4885TYK2 1285/4885PPARG 2956/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | RORC 1254/4885TYK2 1333/4885PPARG 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.